Millendo Therapeutics, Inc.

301 N. Main St., Suite 100
Ann Arbor
Michigan
48104
United States

Tel: 734-845-9000
Fax: 734-332-6198

Show jobs for this employer

71 articles with Millendo Therapeutics, Inc.

  • – Transaction to advance Tempest’s targeted oncology pipeline – - Concurrent $30M PIPE financing expected to close with merger - - Companies to host conference call today at 8:30 a.m. ET -

  • 2021 is off to a hopeful start for some companies, executives and scientists, while others are forced to fold programs and recalibrate.
  • – Further investment in MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist, not planned following initial review of data from Phase 1 clinical study – – Company exploring expanded range of strategic alternatives to maximize its assets –

  • – Phase 1 clinical trial underway for MLE-301, a selective NK3R antagonist being studied for the treatment of vasomotor symptoms (VMS) in menopausal women –

  • The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.
  • Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, today provided a corporate update and reported financial

  • Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 12:35 p.m. EDT. A live webcast of the pre

  • MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist, advancing with first-in-human trials expected to initiate in 3Q20 – – Further investment in nevanimibe for congenital adrenal hyperplasia (CAH) not planned following interim data review – – Strategic evaluation in place to determine future corporate strategy – ANN ARBOR, Mich.--( BUSINESS WIRE )-- Millendo Therapeutics, Inc. (Nasdaq: MLND), a biopharmaceutical company pri

  • Millendo Therapeutics, Inc. (Nasdaq:MLND), a clinical stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, today provided a corporate update and reported financial results for the quarter ended March 31, 2020. “As we wind down activities related to the livoletide program, we have moved quickly to streamline costs and redeploy developme

  • Livoletide did not achieve statistically significant improvement in primary endpoint of change in hyperphagia and food-related behaviors relative to placebo –

  • March 11, 2020 12:30 UTC –Topline results from pivotal Phase 2b study of livoletide in patients with Prader-Willi syndrome (PWS) expected in early 2Q20– –Topline results from first cohort of Phase 2b study of nevanimibe in patients with classic congenital adrenal hyperplasia (CAH) expected in 2H20– –Successful financings strengthen financial position, extending cash runway into 2022– ANN ARBOR, Mich.--( BUSINESS WIRE )-- Millendo Therapeutics, Inc. (Nasdaq:

  • Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, and company management will participate in the following healthcare investor conferences: 32nd Annual ROTH Conference Panel Presentation Date and Time: March 16, 2020

  • Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference in New York City on Wednesday, February 26, 2020 at 2:00 p.m. EST.

  • Feb. 10, 2020 13:30 UTC   Millendo Therapeutics Appoints Christophe Arbet-Engels, MD, PhD, as Chief Medical Officer – Company also provides update on timeline for pivotal ZEPHYR study – ANN ARBOR, Mich.--( BUSINESS WIRE )-- Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced today that Christophe Arbet-Engels, MD, PhD, has joined the company as Chief Medi

  • Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, today announced the promotion of Thomas Hoover to the newly created position of Chief Commercial Officer.

  • Dr. Nichol currently serves as Chief Medical Officer at BioMarin where he oversees an active portfolio of clinical development programs and has led multiple programs through late-stage clinical studies and regulatory approval.

  • Millendo Therapeutics, Inc., a late-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, announced that it has commenced an underwritten public offering of shares of its common stock.

  • The offering is expected to close on December 9, 2019, subject to the satisfaction of customary closing conditions.

  • It was a busy week for clinical trial announcements. Here’s a look.
  • Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, today provided a corporate update and reported financial results for the quarter ended September 30, 2019.